Clinical trials: End Stage Liver Disease
End Stage Liver Disease, Jaundice
SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury
In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury.
- Conditions
- End Stage Liver Disease, Jaundice, Liver Dysfunction, Portal Hypertension
- Trial name
- NCT06173947
- Testing
- FibroScan® Expert 630
- Where
- China
- Volunteers
- 411 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Failure, Acute, Chronic Hepatic Failure
Comparison of Two Liver Dialysis Systems : MARS Versus SPAD in Severe Liver Failure
A critical issue of the clinical syndrome in liver failure is the accumulation of toxins not cleared by the failing liver. Based on this hypothesis, albumin dialysis is used to remove those substances.
- Trial name
- MARSPAD (NCT02310542)
- Testing
- MARS albumin dialysis system, SPAD albumin dialysis system
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Hospices Civils de Lyon
Acute-On-Chronic Liver Failure, Hepatic Encephalopathy
Early Postoperative CRRT After Liver Transplantation in ACLF Patients With Overt HE
Pretransplant hepatoencephalopathy (HE) markedly impacts recipient outcomes after liver transplantation. Intraoperative CRRT showed benefits but feasibility was much concerned.
- Trial name
- LTeCRRT (NCT04317222)
- Testing
- eCRRT
- Volunteers
- 250 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Liver Failure
Nomogram Analysis for HBV Related Acute-on-chronic Liver Failure
Acute-on-chronic liver failure (ACLF) is an acute deterioration of chronic liver diseases, which progresses rapidly, with a mortality rate of more than 50%.MELD score is used to evaluate the patients' condition.
- Trial name
- NCT03992898
- Testing
- No special intervention was suitable for this observational study
- Where
- China
- Volunteers
- 2,739 people
- Sponsor
- Sun Yat-sen University
Liver Transplantation, Immune Tolerance
Immune Tolerance Induction After Liver Transplantation
This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery.
- Conditions
- Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival
- Trial name
- iTILT (NCT07269041)
- Testing
- Donor Hematopoietic Stem and Progenitor Cell Infusion
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Los Angeles
Liver Failure, Cirrhosis
Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial
The methods for separation of mesenchymal stem cell were established in 2001. These cells can differentiate to osteocytes, hepatocytes, chondrocytes, myocytes and etc,.
- Trial name
- NCT00420134
- Testing
- injection of progenitor of hepatocyte drived from Mesenchymal stem cell
- Where
- 2 sites in Iran
- Volunteers
- 30 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Liver Failure, Mesenchymal Stem Cells
Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure
Liver failure (LF) is a dramatic clinical syndrome with massive necrosis of liver cells. and liver transplantation is the only available therapeutic option for patients suffering with this condition.
- Trial name
- NCT01218464
- Testing
- Conventional plus MSC treatment, Conventional plus pacebo treatment
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Beijing 302 Hospital
Acute-On-Chronic Liver Failure
Acute-On-Chronic Liver Failure in Zagazig University Hospitals
Rationale: To identify the prevalence of Acute-on-chronic liver failure in Zagazig University Hospitals. The question of the research: How much the prevalence of Acute-on-chronic Liver Failure in Zagazig University Hospitals? The…
- Trial name
- ACLF (NCT03184636)
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Zagazig University
Hepatitis C Virus (HCV)
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease
This study evaluates the efficacy and safety of ombitasvir/paritaprevir/ritonavir with or without dasabuvir in adults with hepatitis C virus (HCV) genotype 1a (GT1a) or genotype 4 (GT4) infection and with severe kidney impairment…
- Trial name
- NCT02487199
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir
- Volunteers
- 18 people
- Sponsor
- AbbVie
Psoriasis Chronic, Liver Fibrosis
An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis
Main objectives and outcome measures. 1. Establish prevalence of and factors contributing to fatty liver disease and liver fibrosis in patients with psoriasis. Fatty liver disease diagnosed via ultrasound.
- Conditions
- Psoriasis Chronic, Liver Fibrosis, Fatty Liver, Non-alcoholic Fatty Liver Disease
- Trial name
- CORE (NCT02174367)
- Testing
- Transient elastography
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- King's College London
Coronary Artery Disease, Acute Liver Failure
Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct
Coronary Artery Disease (CAD) is the narrowing or blockage of the artery of the heart and is prevalent in end-stage liver disease.
- Conditions
- Coronary Artery Disease, Acute Liver Failure, Liver Transplant
- Trial name
- CRASCH-Liver (NCT04089969)
- Testing
- CTA/FFRct, SOC cardiovascular evaluation
- Sponsor
- Corewell Health East
End Stage Liver Disease
Evaluation of Frailty and Functional Capacity in End-Stage Liver Disease
Development of fibrosis plays a main role in the pathophysiology of liver diseases. The rate of progression in fibrogenesis varies according to the type of underlying liver disease and varies with the environment and host-related…
- Trial name
- NCT04220723
- Testing
- Frailty Assessment, Functional Capacity Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Cancer, Chronic Obstructive Pulmonary Disease
Comparative Trial of Home-Based Palliative Care
Background: To effectively alleviate suffering and improve quality of life for patients with serious illness and their caregivers, palliative care (PC) services must be offered across multiple settings.
- Conditions
- Cancer, Chronic Obstructive Pulmonary Disease, Heart Failure, Dementia
- Trial name
- HomePal (NCT03694431)
- Testing
- Tech-supported HBPC, Standard HBPC
- Where
- 2 sites in United States
- Volunteers
- 3,999 people
- Sponsor
- Kaiser Permanente